Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine

Chong Guo; Chaoying Song; Jiali Zhang; Yisong Gao; Yuying Qi; Zongyao Zhao; Chengfu Yuan

doi:10.1016/j.gendis.2020.11.017

您当前的位置：

首页 >

文章列表页 >

Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine

更新时间：2022-06-24

- Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
- Genes & Diseases Vol. 9, Issue 3, (2022)
- 作者机构：
  
  1. College of Medical Science, China Three Gorges University,Hubei,Yichang,PR China,443002
  2. Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, China Three Gorges University,Hubei,Yichang,PR China,443002
  3. Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University,Hubei,Yichang,PR China,443002
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2020.11.017
  CLC：
- Published：2022，
  
  Published Online：1 May 2022，
扫描看全文
Chong Guo, Chaoying Song, Jiali Zhang, et al. Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine. [J]. Genes & Diseases 9(3).(2022)
DOI：

Chong Guo, Chaoying Song, Jiali Zhang, et al. Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine. [J]. Genes & Diseases 9(3).(2022) DOI： 10.1016/j.gendis.2020.11.017.

摘要

Abstract

mong the gynecological cancers

ovarian cancer is the most lethal. Its therapeutic options include a combination of chemotherapy with platinum-based compounds and cytoreductive surgery. Most ovarian cancer patients exhibit an initial response to platinum-based therapy

however

platinum resistance has led to up to 80% of this responsive cohort becoming refractory. Ovarian cancer recurrence and drug resistance to current chemotherapeutic options is a global challenge. Chemo-resistance is a complex phenomenon that involves multiple genes and signal transduction pathways. Therefore

it is important to elucidate on the underlying molecular mechanisms involved in chemo-resistance. This inform decisions regarding therapeutic management and help in the identification of novel and effective drug targets. Studies have documented the individual biomarkers of platinum-resistance in ovarian cancer that are potential therapeutic targets. This review summarizes the molecular mechanisms of platinum resistance in ovarian cancer

novel drug targets

and clinical outcomes.

关键词

Keywords

Clinical outcomesMechanismsMolecular biomarkersOvarian cancerPlatinum resistance

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer

Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine

Ubiquitin ligase DTX3 empowers mutant p53 to promote ovarian cancer development

Related Author

Xiawei Wei

Xia Zhao

Tianqi Lu

Yanfei Yang

Xiaoyi Hu

Yang Yang

Weiqi Hong

Qingfang Li

Related Institution

Department of Gynecology and Obstetrics, Development and Related Disease of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University

Department of Obstetrics and Gynecology, The First Affiliated Hospital, Army Medical University

Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University

Faculty of Applied Science and Biotechnology, Shoolini University, Solan, Himachal Pradesh

Vascular Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School

⁰